<DOC>
	<DOCNO>NCT00437450</DOCNO>
	<brief_summary>The purpose study - To evaluate efficacy association Erythropoetin ( Neorecormon ) ATRA patient low risk myelodysplastic syndrome - To evaluate tolerance treatment</brief_summary>
	<brief_title>Treatment Anemia Myelodysplastic Syndromes Association Epoetin Beta All Trans Retinoic Acid</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Tretinoin</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>Patients ≥18 year RA , RARS , RAEB ( blast &lt; 10 % ) Hb &lt; 10g/dl &gt; 2 month transfuse since less 2 month Hb &lt; 12g/dl &gt; 2 month thrombocytopenia define platelet &lt; 50 000/mm3 , neutropenia &lt; 10 000mm3 For woman child bearing age , necessity contraception duration study Patient lung disease , cardiac , neurological , gastrointestinal genito urinary disorder connect genito urinary connect myelodysplasia Patient receive intensive chemotherapy 3 month inclusion protocol RAEBt RAEB &gt; 10 % blast Treatment rHuEpo , darbepoetin ou rHuGCSF , 2 month inclusion Patient presenting iron , B12 vitamin folic acid uncorrected deficit CMML Uncontrolled systemic hypertension creatinine clearance &lt; 300 µM/L Pregnant patient period lactation Life expectancy &lt; 6 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2007</verification_date>
	<keyword>Anemia</keyword>
	<keyword>myelodysplastic syndrome</keyword>
	<keyword>Low risk</keyword>
	<keyword>Bone Marrow disease</keyword>
</DOC>